Here Come More Gene Therapies -- And More Pricing Debates


Gene therapies like Spark Therapeutics' upcoming Luxturna and Novartis' FDA-approved Kymriah are raising concerns about the rising cost of health care, leading some experts to suggest new ways to price treatments based on the benefits they offer.
Source link